| Literature DB >> 28981562 |
Natália O Mota1, Elza M Kimura1, Roberta D Ferreira1, Gisele A Pedroso1, Dulcinéia M Albuquerque2, Daniela M Ribeiro1, Magnun N N Santos1, Cristina M Bittar3, Fernando F Costa2, Maria de Fatima Sonati1.
Abstract
Alpha-thalassemias are among the most common genetic diseases in the world. They are characterized by hypochromic and microcytic anemia and great clinical variability, ranging from a practically asymptomatic phenotype to severe anemia, which can lead to intrauterine or early neonatal death. Deletions affecting the α-globin genes, located on chromosome 16p13.3, are the main causes of α-thalassemia. Multiplex ligation-dependent probe amplification (MLPA) can be used to detect rearrangements that cause α-thalassemia, particularly large deletions involving the whole α cluster and/or deletions in the HS-40 region. Here, MLPA was used to investigate the molecular basis of α-thalassemia in five unrelated patients, three of whom had Hb H disease. In addition to the -α3.7 deletion identified in the patients with Hb H disease, four different α0 deletions removing 15 to 225 kb DNA segments were found: two of them remove both the α genes, one affects only the regulatory element (HS-40) region, and another one extends over the entire α cluster and the HS-40 region. These results illustrate the diversity of α-thalassemia deletions in the Brazilian population and highlight the importance of molecular investigation in cases that present with microcytosis and hypochromia without iron deficiency and normal or reduced Hb A2 levels..Entities:
Year: 2017 PMID: 28981562 PMCID: PMC5738609 DOI: 10.1590/1678-4685-GMB-2016-0330
Source DB: PubMed Journal: Genet Mol Biol ISSN: 1415-4757 Impact factor: 1.771
Hematological and molecular data of Patients P1 - P3 and their families, and P4.
| Cases | P1 | MP1 | FP1 | BP1 | P2 | MP2 | FP2 | BP2 | P3 | DP3 | P4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age/Gender | 17/M | 42/F | 42/M | 14/M | 35/F | -/F | -/M | -/M | 58/F | 24/F | 22/F |
| RBC (106/mm3) | 5.43 | 4.79 | 6.61 | 4.94 | 5.50 | 5.72 | 3.94 | 5.64 | 5.50 | 5.60 | 5.00 |
| RV: M: 4.5-6.1/F: 4.2-5.4 | |||||||||||
| Hb (g/dL) | 8.8 | 12.4 | 13.5 | 12.3 | 11.2 | 11.8 | 13 | 11.7 | 12.5 | 11.8 | 8.3 |
| RV: M: 14-18/F: 12-16 | |||||||||||
| MCV (fL) | 56 | 80.2 | 66.9 | 77.7 | 65.3 | 68.2 | 100.8 | 66.7 | 70.4 | 65.4 | 59.4 |
| RV: M: 81-99/F: 80-96 | |||||||||||
| MHC (pg) | 16.2 | 25.9 | 20.4 | 24.9 | 20.4 | 20.6 | 33 | 20.7 | 22.4 | 21.1 | 16.6 |
| RV: 27-32 | |||||||||||
| Hb profile | A2,A,H | A2,A | A2,A | A2,A | A2,A | A2,A | A2,A | A2,A | A2,A | A2,A | A2,A,H |
| Hb A2 (%) | 1.6 | 2.9 | 2.4 | 2.8 | 2.6 | 2.4 | 2.6 | 2.7 | 2.5 | - | 0.8 |
| RV: 1.5- 3.5 | |||||||||||
| Hb F (%) | 0.1 | 0.3 | 0.2 | 0.3 | 0.6 | 0.7 | 0.3 | 0.6 | 0.4 | - | 1.7 |
| RV: < 2 | |||||||||||
| α-Genotype | --/-α3,7 | -α3,7/αα | --/αα | -α3,7/αα | --/αα | --/αα | αα /αα | --/αα | --/αα | --/αα | --/-α3,7 |
P: patient; MP: mother of the patient; FP: father of the patient; BP: brother of the patient; DP: daughter of the patient; M: male; F: female; RBC: red blood cells; RV: reference values; Hb: total hemoglobin; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin.
Hematological and molecular data of Patient P5 and her family.
| Cases | P5 | MP5 | FP5 | BP5 | BP5 | SP5 | SP5 | BP5 | BP5 |
|---|---|---|---|---|---|---|---|---|---|
| Age/Gender | 2m/F | 40/F | 46/M | 10/M | 13/M | 18/F | 19/F | 20/M | 22/M |
| RBC (106/mm3) | 4.64 | 5.41 | 5.51 | 5.26 | 5.97 | 5.34 | 5.47 | 5.33 | 5.49 |
| RV: M: 4.5-6.1/F: 4.2-5.4 | |||||||||
| Hb (g/dL) | 8.1 | 14.3 | 12.8 | 8.9 | 9.9 | 11.3 | 11.4 | 16.2 | 14.5 |
| RV: M: 14-18/F: 12-16 | |||||||||
| MCV (fL) | 62.3 | 81.9 | 72.4 | 61.8 | 59.6 | 68.9 | 66.7 | 89.1 | 83.6 |
| RV: M: 81-99/F: 80-96 | |||||||||
| MHC(pg) | 17.5 | 26.4 | 23.2 | 16.9 | 16.6 | 21.2 | 20.8 | 30.4 | 26.4 |
| RV: 27-32 | |||||||||
| Hb profile | A2,A,H, Bart's | A2,A | A2,A | A2,A,H | A2,A,H | A2,A | A2,A | A2,A | A2,A |
| Hb A2 (%) | 1.0 | 2.5 | 1.7 | 1.6 | 1.8 | 2.7 | 2.7 | 2.7 | 0.1 |
| RV: 1.5- 3.5 | |||||||||
| Hb F (%) | 22.6 | 0.2 | 0.3 | 0.1 | 0.1 | 0.2 | 0.1 | 0 | 2.2 |
| RV: < 2 | |||||||||
| α-Genotype | --/-α3,7 | -α3,7/αα | --/αα | --/-α3,7 | --/-α3,7 | --/αα | --/αα | αα /αα | -α3,7/αα |
P: patient; MP: mother of the patient; FP: father of the patient; BP: brother of the patient; SP: sister of the patient; m: months; M: male; F: female; RBC: red blood cells; RV: reference values; Hb: total hemoglobin; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin.
Figure 1Schematic representation of chromosome 16p13.3. The oval represents the telomeric region, the arrows the locations of the probes and the boxes the genes. The black bars correspond to the deleted fragments, the dotted lines denote the first and last deleted probes delimiting the segments containing the breakpoints (adapted from MRC-Holland, provider of the MLPA kit).
Figure 2Pedigrees of the families studied. (A) P1 has Hb H disease (-α3.7 and α0 alleles), while his mother and brother are heterozygous for the -α3.7 deletion and his father for the α0 deletion. (B) P2 and her mother and brother are heterozygous for the α0 deletion, while her father has normal α-genotype (no deletion). (C) P3 and her daughter are heterozygous for the α0 deletion. (D) P5 and two of her brothers have Hb H disease (-α3.7 and α0 alleles); her mother and two sisters are heterozygous for the -α3.7 deletion, while her father and one of her brothers are heterozygous for the α0 deletion. Only one of the siblings does not have any deletions.